Buchumschlag

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yan Li, Cunzhen Shi, Jiazhuo Wu, Xiaoyan Feng, Wenting Song, Mengyuan Jin, Yu Chang, Lijuan Han, Ping Zhang, Yuqin Song, Jun Zhu, Mingzhi Zhang
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Veröffentlicht: (2026)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
von: Rui Sun, et al.
Veröffentlicht: (2026)

Comprehensive Analysis of Single‐Cell and Bulk Transcriptomics Identified Regulatory T‐Cell Features as Predictors of Prognosis in Diffuse Large B‐Cell Lymphoma
von: Yaoli Cui, et al.
Veröffentlicht: (2025)

Knockdown of VDAC1 Promotes Ferroptosis in Diffuse Large B‐Cell Lymphoma
von: Chuanming Lin, et al.
Veröffentlicht: (2025)

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
von: Allison M. Bock, et al.
Veröffentlicht: (2024)

Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment
von: Peter Borchmann, et al.
Veröffentlicht: (2025)

Peripheral T‐Cell Lymphoma: What's Next?
von: Sang Eun Yoon, et al.
Veröffentlicht: (2025)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
von: Pier Luigi Zinzani, et al.
Veröffentlicht: (2025)

Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China
von: Jiajie He, et al.
Veröffentlicht: (2026)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
von: Ganggang Wang, et al.
Veröffentlicht: (2025)

Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma
von: Sara Ovejero, et al.
Veröffentlicht: (2025)

Oncogenic IRF3 Signaling Promotes Diffused Large B‐Cell Lymphoma Proliferation by Cyclin D3/CDK4‐Dependent Cell Cycle Control
von: Bide Zhao, et al.
Veröffentlicht: (2025)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
von: Yue Zhao, et al.
Veröffentlicht: (2025)

Treatments and Outcomes of Newly Diagnosed CD5‐Positive Diffuse Large B‐Cell Lymphoma: A Multi‐Institutional Observational Study
von: Yuma Nato, et al.
Veröffentlicht: (2025)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
von: Simone Ferrero, et al.
Veröffentlicht: (2025)

Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study
von: Pallawi Torka, et al.
Veröffentlicht: (2025)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
von: Hazim S. Ababneh, et al.
Veröffentlicht: (2024)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
von: Meirav Kedmi, et al.
Veröffentlicht: (2024)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
von: Yoshikazu Ikoma, et al.
Veröffentlicht: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
von: Jinyan Xiao, et al.
Veröffentlicht: (2025)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
von: Juliette Penichoux, et al.
Veröffentlicht: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
von: Yutaka Shimazu, et al.
Veröffentlicht: (2025)

Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center Experience
von: Alexandra Zduniak, et al.
Veröffentlicht: (2025)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
von: Minna Harmanen, et al.
Veröffentlicht: (2025)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
von: Inna Y. Gong, et al.
Veröffentlicht: (2026)

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
von: E. Silkenstedt, et al.
Veröffentlicht: (2025)

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma
von: Gabriela Forestieri, et al.
Veröffentlicht: (2024)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
von: Tengfei Shi, et al.
Veröffentlicht: (2025)

ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway
von: Yamei Chen, et al.
Veröffentlicht: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Veröffentlicht: (2025)

Comparative Effectiveness of R‐miniCOMP Versus R‐miniCHOP in Older Non‐Fit Patients With Diffuse Large B‐Cell Lymphoma: Insights From a “Fondazione Italiana Linfomi” Cohort Study
von: Alberto Bavieri, et al.
Veröffentlicht: (2025)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
von: Oskar Steinbrecher, et al.
Veröffentlicht: (2024)

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
von: Emil Kumar, et al.
Veröffentlicht: (2025)

Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto‐HCT in Lymphomas
von: Rafaella Cabral Samico, et al.
Veröffentlicht: (2025)

Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma
von: Zhiqiang Song, et al.
Veröffentlicht: (2026)

Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
von: Akihiko Izumi, et al.
Veröffentlicht: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
von: J.T. Jutzi, et al.
Veröffentlicht: (2025)

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2‐[ 18 F]FDG PET/CT in Advanced Mantle Cell Lymphoma
von: Domenico Albano, et al.
Veröffentlicht: (2024)

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma
von: Hazim S. Ababneh, et al.
Veröffentlicht: (2024)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
von: Giacomo Loseto, et al.
Veröffentlicht: (2025)